Form 4: Celldex Therapeutics CFO Granted 81,000 Stock Options Under Equity Incentive Plan

Celldex Therapeutics' Senior Vice President and Chief Financial Officer, Samuel Bates Martin, was granted 81,000 incentive stock options with a vesting schedule extending through 2029.

Summary

• Samuel Bates Martin, SVP and CFO of Celldex Therapeutics, Inc. (CLDX), was granted 81,000 incentive stock options on June 5, 2025.
• These options have an exercise price of $19.53 per share.
• The grant was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan.
• The options begin vesting on June 5, 2026, with 25% vesting on that date, and the remaining 75% vesting quarterly in equal amounts over the subsequent 12 quarters (3 years).
• The options expire on June 5, 2035.

Sentiment

Score: 6

Explanation: The document reports a routine executive compensation event (stock option grant). While not directly impacting immediate financial results, it reflects standard corporate governance and incentive alignment practices, which is generally positive for long-term stability and management retention.

Positives

• Aligns management's interests with shareholder value through equity incentives.
• Provides long-term retention incentive for a key executive.
• Demonstrates the company's commitment to its executive compensation strategy.

Negatives

• Potential for future dilution if options are exercised, although this is a standard part of equity compensation plans.
• The value of the options is dependent on future stock price appreciation, introducing market risk for the executive.

Risks

• Dilution Risk: Exercise of these options in the future will increase the number of outstanding shares, potentially diluting existing shareholders' ownership percentage.
• Market Price Volatility: The ultimate value realized from these options by the CFO is directly tied to the future market price of Celldex Therapeutics' common stock, which is subject to market fluctuations.
• Compensation Expense: The grant of these options will result in a non-cash compensation expense for the company over the vesting period, impacting reported earnings.

Future Outlook

The document does not contain explicit forward-looking statements or guidance regarding the company's financial performance or strategic direction, beyond the future vesting schedule of the granted options.

Industry Context

The granting of stock options to key executives like the CFO is a standard practice in the biotechnology and pharmaceutical industries, aiming to align executive incentives with long-term shareholder value creation and to retain talent in a competitive market. This practice is common across publicly traded companies, particularly those in growth-oriented sectors.

Comparison to Industry Standards

• The structure of this option grant, including the vesting schedule (25% after one year, then quarterly over three years) and a 10-year expiration period, is consistent with typical equity compensation practices observed in the biotechnology and broader public company landscape.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar long-term incentive plans to compensate and retain their senior executives, often tying a significant portion of executive compensation to equity performance.

Corporate Governance

Related Party Transactions

• The grant of incentive stock options to Samuel Bates Martin, a senior executive (SVP and CFO), constitutes a related party transaction as it involves compensation provided by the company to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for future dilution upon exercise of options; however, the grant aims to align management's interests with shareholder value creation.
• Employees: Reflects the company's compensation philosophy, potentially influencing morale and retention of other key personnel.
• Management: Provides a significant long-term incentive and a direct stake in the company's future performance.

Next Steps

• The granted options will begin vesting on June 5, 2026, with subsequent quarterly vesting over the following three years.
• The options will remain exercisable until their expiration date of June 5, 2035.

Key Dates

Keywords

Celldex Therapeutics, CLDX, Form 4, SEC Filing, Stock Options, Incentive Stock Option, Equity Compensation, Executive Compensation, Samuel Bates Martin, CFO, Vesting Schedule, Omnibus Equity Incentive Plan